TP53 and hepatocellular carcinoma: Our study showed that HCC patients in the high-score-risk group had a higher frequency of TP53 mutations and a worse prognosis, which is consistent with the study by Tang et al (72).In recent years, the use of immunotherapy in the treatment of HCC has attracted increasing attention (73), and checkpoint inhibitor immunotherapy plays an important role in HCC patients (74).